Arbutus와 Vaccitech, 만성 B형 간염 바이러스 치료용 병용 요법에 대한 임상2a상 시험에서 첫 환자 투여
04 juin 2022 09h43 HE
|
Vaccitech (UK) Limited
미국 펜실베이니아주 워민스터/영국 옥스포드, June 04, 2022 (GLOBE NEWSWIRE) -- 광범위한 바이러스학 전문성을 활용해 특정 바이러스 질환 치료용 신약을 개발하는 임상 단계 바이오 제약사인 Arbutus Biopharma Corporation (Nasdaq: ABUS)과 새로운 면역치료제와 백신에 대한 발견 및 개발을 전문으로 하는...
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
20 mai 2022 11h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments
11 mai 2022 16h15 HE
|
Vaccitech plc
OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of...
Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®
06 avr. 2022 16h15 HE
|
Vaccitech plc
OXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments
25 mars 2022 07h15 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of...
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
07 mars 2022 08h00 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
18 janv. 2022 03h00 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient...
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
13 janv. 2022 16h34 HE
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
13 déc. 2021 16h05 HE
|
Vaccitech (UK) Limited
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities.Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM...
Vaccitech在慢性HBV的1b/2a期临床研究中报告了极具前景的中期疗效分析
07 déc. 2021 10h30 HE
|
Vaccitech (UK) Limited
在慢性乙型肝炎（CHB）患者中，27名完成了3个月HBV002研究患者的中期数据表明，表面抗原（HBsAg）水平出现了显著变化，特别是在接受具有异源加强型（VTP-300）低剂量纳武单抗的人群中。 HBV002研究招募了4个组来探索初免-加强载体组合，其中包括MVA-HBV（初免）+ MVA-HBV（加强）、ChAdOx1-HBV（初免）+...